Skip to main content
GYRE
NASDAQ Life Sciences

Gyre Therapeutics Registers $176.5M Resale of Shares by Former Cullgen Stockholders

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$6.34
Mkt Cap
$594.573M
52W Low
$5.44
52W High
$9.42
52W Position info
17% above low
Off High info
33% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

GYRE sits 17% above its 52-week low of $5.44.

Summary

Gyre Therapeutics filed an S-3 registration statement to allow former Cullgen Inc. stockholders to resell up to 30.2 million shares, valued at $176.5 million, following the recent all-stock acquisition.


Key Events · Financing and Capital Events · GYRE

  • Resale Registration Filed

    Gyre Therapeutics filed an S-3 registration statement for the resale of up to 30,221,531 shares of common stock.

  • Shares from Cullgen Acquisition

    These shares were issued to former stockholders of Cullgen Inc. as part of the all-stock merger completed on May 4, 2026.

  • Significant Potential Dilution

    The registered shares represent approximately 27.1% of the company's currently outstanding common stock.

  • No Proceeds to Company

    Gyre Therapeutics will not receive any proceeds from the sale of these shares by the selling stockholders.


Analysis · GYRE · Life Sciences

Gyre Therapeutics filed an S-3 registration statement to allow former Cullgen Inc. stockholders to resell up to 30.2 million shares, valued at $176.5 million. These shares were issued as consideration in the all-stock acquisition of Cullgen completed on May 4, 2026. The company will not receive any proceeds from these sales. While the shares are subject to staggered lock-up agreements, the registration of such a substantial volume (approximately 27.1% of current outstanding shares) creates a significant overhang on the stock, indicating potential future selling pressure from these large shareholders.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GYRE was trading at $6.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $594.6M. The 52-week trading range was $5.44 to $9.42. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GYRE - Latest Insights

GYRE
Nov 05, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $4.53 info
Change: +$0.520 (+13%) info
Market Cap: $521.251M info
GYRE
Nov 05, 2026, 4:07 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $4.53 info
Change: +$0.520 (+13%) info
Market Cap: $521.251M info
GYRE
Aug 07, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.67
Real-time Price: $4.53 info
Change: -$2.14 (-32%) info
Market Cap: $521.251M info
GYRE
Aug 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.40
Real-time Price: $4.53 info
Change: -$1.87 (-29%) info
Market Cap: $521.251M info
GYRE
Jul 15, 2026, 5:09 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $6.56
Real-time Price: $4.53 info
Change: -$2.03 (-31%) info
Market Cap: $521.251M info